Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imricor Medical SystemsASX:IMR 43 OCF Margin % is -10,484.62% as of Dec. 2025. GuruFocus rates ASX:IMR with a GF Score™ of 43/100 and a GF Value™ of A$0.10 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Imricor Medical Systems ranks worse than 98.28% on this metric.
The historical rank and industry rank for Imricor Medical Systems's OCF Margin % or its related term are showing as below:
ASX:IMR'
s OCF Margin % Range Over the Past 10 Years
Min: -6541.46 Med: -2023.82 Max: -1035.95
Current: -6502.24
During the past 8 years, the highest OCF Margin % of Imricor Medical Systems was -1035.95%. The lowest was -6541.46%. And the median was -2023.82%.
ASX:IMR's OCF Margin % is ranked worse than 98.28% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 5.785
vs ASX:IMR: -6502.24
Imricor Medical Systems OCF Margin % Related Terms
Imricor Medical Systems OCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Imricor Medical Systems's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imricor Medical Systems OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Imricor Medical Systems's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Imricor Medical Systems's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imricor Medical Systems (ASX:IMR) has a OCF Margin % of -10,484.62% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Imricor Medical Systems and its competitors. According to the industry distribution chart, Imricor Medical Systems ranks #802 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 98.3%.
Is Imricor Medical Systems' OCF Margin % too high?
Imricor Medical Systems' current OCF Margin % is -10,484.62%. Based on the distribution chart, Imricor Medical Systems ranks #802 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Imricor Medical Systems has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Imricor Medical Systems' OCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Imricor Medical Systems ranks #802 out of 816 companies for OCF Margin %. This places Imricor Medical Systems in the lower half of its industry. The industry median OCF Margin % is 5.79. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.79, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Imricor Medical Systems and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imricor Medical Systems's current OCF Margin % is -10,484.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imricor Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Imricor Medical Systems (ASX:IMR) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.10, compared to a current price of A$1.83 — trading 1725% above its estimated fair value. The current OCF Margin % is -10,484.62%. Imricor Medical Systems' overall GF Score™ is 43/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Imricor Medical Systems (ASX:IMR), the current OCF Margin % is -10,484.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imricor Medical Systems (ASX:IMR) Overvalued in 2026?
Based on GuruFocus' analysis, Imricor Medical Systems stock appears to be overvalued.
The current stock price of A$1.83 is trading 1725% above its estimated GF Value™ of A$0.10.
GuruFocus considers Imricor Medical Systems to be Significantly Overvalued.
Key valuation signals for ASX:IMR:
OCF Margin %: -10,484.62%
GF Value™: A$0.10 vs. price of A$1.83 (1725% above fair value)
No single metric tells the full story. See the ASX:IMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imricor Medical Systems Inc is a medical device company that develops MRI-guided technology to address issues with traditional X-ray ablation procedures. Its principal business activities are designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The company's products include the Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter, and Vision-MR Dispersive Electrode. Geographically, the company generates maximum revenue from Europe.
43GF Score
Get the complete analysis for ASX:IMR
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IMR has been successfully added to your 
